TY  - GEN
AU  - Moy,Beverly
AU  - Neven,Patrick
AU  - Lebrun,Fabienne
AU  - Bellet,Meritxell
AU  - Xu,Binghe
AU  - Sarosiek,Tomasz
AU  - Chow,Louis
AU  - Goss,Paul
AU  - Zacharchuk,Charles
AU  - Leip,Eric
AU  - Turnbull,Kathleen
AU  - Bardy-Bouxin,Nathalie
AU  - Duvillié,Ladan
AU  - Láng,István
TI  - Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer
SN  - 1549-490X
PY  - 2015///0112
KW  - Aniline Compounds
KW  - adverse effects
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Aromatase Inhibitors
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Letrozole
KW  - Nitriles
KW  - Postmenopause
KW  - Protein Kinase Inhibitors
KW  - Quinolines
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Triazoles
N1  - Publication Type: Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1634/theoncologist.2014-0021
ER  -